Company intelligence / Profile preview
TiumBio Co., Ltd.
Seongnam-si, Gyeonggi-do, South Koreatiumbio.com ↗
- Ownership
- Private
- Development stage
- Phase 2
01
Overview
TiumBio has reported positive results from a Phase 1a clinical trial for its hemophilia treatment TU7710, which showed potential as a long‑acting recombinant activated factor VII. The company has also initiated a Phase 2 trial of its oral immuno-oncology drug TU2218, targeting the TGF‑β pathway. Its GnRH antagonist program for endometriosis has advanced to clinical trials in partnership with Hansoh Pharma
- Therapeutic areas
- OtherWomen's HealthOncologyHematology
- Modalities
- Small moleculesBiologics (recombinant proteins)
- Industry
- Biotech
02
Drug pipeline
8 assets7 more assets in the full pipeline.
03
Partnerships
Hansoh Pharma (China): For development and commercialization of Merigolix/TU2670 in reproductive health indications including ART/IVF applications.Oncodesign Société Anonyme (France): Collaboration on fibrosis drug candidates research and development
Beyond the preview
Go deeper on TiumBio Co., Ltd..
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on TiumBio Co., Ltd..